{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:19:28Z","timestamp":1763641168135,"version":"3.45.0"},"reference-count":30,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dan Med J"],"abstract":"<jats:p>Systematic PSA-based screening for prostate cancer remains controversial due to the trade-off between reduced mortality and risk of overdiagnosis and overtreatment. Adding new tools like magnetic-resonance-imaging-targeted biopsies and genetic markers may limit the harms, but we lack definitive mortality data. While opportunistic PSA testing is widely used in Denmark, unsystematic use may potentially be harmful. Introduction of a systematic screening programme in Denmark requires careful consideration of the clinical, psychological, societal and economic impacts, and Danish politicians should thus engage in the debate to clarify these issues.<\/jats:p>","DOI":"10.61409\/a09250711","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:05:11Z","timestamp":1761901511000},"page":"1-8","source":"Crossref","is-referenced-by-count":0,"title":["Pro and con for systematic screening for prostate cancer in Denmark - a review article"],"prefix":"10.61409","author":[{"given":"Signe Benzon","family":"Larsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"R\u00f8der","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2025,10]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229-263. https:\/\/doi.org\/10.3322\/caac.21834","DOI":"10.3322\/caac.21834"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, Agoritsas T, Dahm P. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018;362:k3519. https:\/\/doi.org\/10.1136\/bmj.k3519","DOI":"10.1136\/bmj.k3519"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Hugosson J, Roobol MJ, M\u00e5nsson M, et al. A 16-yr follow-up of the European Randomized Study of Screening for Prostate Cancer. Eur Urol. 2019;76:43-51. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.009","DOI":"10.1016\/j.eururo.2019.02.009"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013;CD004720. https:\/\/doi.org\/10.1002\/14651858.CD004720.pub3","DOI":"10.1002\/14651858.CD004720.pub3"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Raychaudhuri R, Lin DW, Montgomery RB. Prostate cancer. JAMA. 2025;333:1433. https:\/\/doi.org\/10.1001\/jama.2025.0228","DOI":"10.1001\/jama.2025.0228"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Schr\u00f6der FH, Bangma CH. The European Randomized Study of Screening for Prostate Cancer (ERSPC). Br J Urol. 1997;79:68-71. https:\/\/doi.org\/10.1111\/j.1464-410X.1997.tb00804.x","DOI":"10.1111\/j.1464-410X.1997.tb00804.x"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Otto SJ, Moss SM, M\u00e4\u00e4tt\u00e4nen L, et al. PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer. Eur J Cancer. 2010;46:3053-3060. https:\/\/doi.org\/10.1016\/j.ejca.2010.09.012","DOI":"10.1016\/j.ejca.2010.09.012"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Pasanen N, Talala K, Remmers S, et al. Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer. BJU Int. 2024;134:291-299. https:\/\/doi.org\/10.1111\/bju.16394","DOI":"10.1111\/bju.16394"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;319:1914-1931. https:\/\/doi.org\/10.1001\/jama.2018.3712","DOI":"10.1001\/jama.2018.3712"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"van Harten MJ, Roobol MJ, van Leeuwen PJ, Willemse PPM, van den Bergh RCN. Evolution of European prostate cancer screening protocols and summary of ongoing trials. BJU Int. 2024;134:1-12. https:\/\/doi.org\/10.1111\/bju.16311","DOI":"10.1111\/bju.16311"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Van Poppel H, Hogenhout R, Albers P, van den Bergh RCN, Barentsz JO, Roobol MJ. Early detection of prostate cancer in 2020 and beyond: facts and recommendations for the European Union and the European Commission. Eur Urol. 2021;79:327-329. https:\/\/doi.org\/10.1016\/j.eururo.2020.12.010","DOI":"10.1016\/j.eururo.2020.12.010"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Kohestani K, M\u00e5nsson M, Godtman RA, et al. The G\u00f6teborg prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate. Scand J Urol. 2021;55:116-124. https:\/\/doi.org\/10.1080\/21681805.2021.1881612","DOI":"10.1080\/21681805.2021.1881612"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Bj\u00f6rnebo L, Discacciati A, Falagario U, et al. Biomarker vs MRI-enhanced strategies for prostate cancer screening: the STHLM3-MRI randomized clinical trial. JAMA Netw Open. 2024;7:e247131. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.7131","DOI":"10.1001\/jamanetworkopen.2024.7131"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Auvinen A, Rannikko A, Taari K, et al. A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale. Eur J Epidemiol. 2017;32:521-527. https:\/\/doi.org\/10.1007\/s10654-017-0292-5","DOI":"10.1007\/s10654-017-0292-5"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Arsov C, Albers P, Herkommer K, et al. A randomized trial of risk-adapted screening for prostate cancer in young men-results of the first screening round of the PROBASE trial. Int J Cancer. 2022;150:1861-1869. https:\/\/doi.org\/10.1002\/ijc.33940","DOI":"10.1002\/ijc.33940"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Cuzick J, Thorat MA, Andriole G, et al. Prevention and early detection of prostate cancer. Lancet Oncol. 2014;15:e484-e492. https:\/\/doi.org\/10.1016\/S1470-2045(14)70211-6","DOI":"10.1016\/S1470-2045(14)70211-6"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Eklund M, J\u00e4derling F, Discacciati A, et al. MRI-targeted or standard biopsy in prostate cancer screening. N Engl J Med. 2021;385:908-920. https:\/\/doi.org\/10.1056\/NEJMoa2100852","DOI":"10.1056\/NEJMoa2100852"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Hugosson J, Godtman RA, Wallstrom J, et al. Results after four years of screening for prostate cancer with PSA and MRI. N Engl J Med. 2024;391:1083-1095. https:\/\/doi.org\/10.1056\/NEJMoa2406050","DOI":"10.1056\/NEJMoa2406050"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Al-Monajjed R, Boschheidgen M, Lakes J, et al. Prostate cancer detection in younger men: a comparative analysis of systematic and magnetic resonance imaging-targeted biopsy in the PROBASE trial. Eur Urol. 2025. https:\/\/doi.org\/10.1016\/j.eururo.2025.05.020","DOI":"10.1016\/j.eururo.2025.05.020"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Kohestani K, Chilov M, Carlsson SV. Prostate cancer screening-when to start and how to screen? Transl Androl Urol. 2018;7:34-45. https:\/\/doi.org\/10.21037\/tau.2017.12.25","DOI":"10.21037\/tau.2017.12.25"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Carlsson SV, Godtman RA, Pihl CG, et al. Young age on starting prostate-specific antigen testing is associated with a greater reduction in prostate cancer mortality: 24-year follow-up of the G\u00f6teborg randomized population-based prostate cancer screening trial. Eur Urol. 2023;83:103-109. https:\/\/doi.org\/10.1016\/j.eururo.2022.10.006","DOI":"10.1016\/j.eururo.2022.10.006"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Hern\u00e1ndez-Leal MJ, P\u00e9rez-Lacasta MJ, Feijoo-Cid M, Ramos-Garc\u00eda V, Carles-Lavila M. Healthcare professionals' behaviour regarding the implementation of shared decision-making in screening programmes: a systematic review. Patient Educ Couns. 2021;104:1933-1944. https:\/\/doi.org\/10.1016\/j.pec.2021.01.032","DOI":"10.1016\/j.pec.2021.01.032"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Hugosson J. Stopping screening, when and how? Transl Androl Urol. 2018;7:46-53. https:\/\/doi.org\/10.21037\/tau.2017.12.39","DOI":"10.21037\/tau.2017.12.39"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Andersen MCM, Stroomberg HV, Brasso K, Helgstrand JT, R\u00f8der A. Diagnostic age, age at death and stage migration in men dying with or from prostate cancer in Denmark. Diagnostics. 2022;12:1271. https:\/\/doi.org\/10.3390\/diagnostics12051271","DOI":"10.3390\/diagnostics12051271"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Auvinen A, Tammela TLJ, Mirtti T, et al. Prostate cancer screening with PSA, kallikrein panel, and MRI: the ProScreen randomized trial. JAMA. 2024;331:1452-1459. https:\/\/doi.org\/10.1001\/jama.2024.3841","DOI":"10.1001\/jama.2024.3841"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Schr\u00f6der FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384:2027-2035. https:\/\/doi.org\/10.1016\/S0140-6736(14)60525-0","DOI":"10.1016\/S0140-6736(14)60525-0"},{"key":"ref26","unstructured":"Danish Health Authority. De nationale screeningsprogrammer for kr\u00e6ft [The national screening programmes for cancer]. Copenhagen; 2022"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes 12 years after localized prostate cancer treatment. NEJM Evid. 2023;2. https:\/\/doi.org\/10.1056\/evidoa2300018","DOI":"10.1056\/EVIDoa2300018"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388:1547-1558. https:\/\/doi.org\/10.1056\/NEJMoa2214122","DOI":"10.1056\/NEJMoa2214122"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Engel JC, Palsdottir T, Aly M, et al. Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50-69 years with PSA \u22653 ng\/ml. Scand J Urol. 2020;54:1-6. https:\/\/doi.org\/10.1080\/21681805.2019.1703806","DOI":"10.1080\/21681805.2019.1703806"}],"container-title":["Danish Medical Journal"],"original-title":[],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:07:19Z","timestamp":1763640439000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/dmj\/A09250711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":30,"URL":"https:\/\/doi.org\/10.61409\/a09250711","relation":{},"ISSN":["2245-1919"],"issn-type":[{"type":"electronic","value":"2245-1919"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}